Suppr超能文献

立体定向体部放疗中使用稳定透明质酸间隔物治疗腹膜后癌:病例系列与剂量学分析

Utilization of a stabilized hyaluronic acid spacer in SBRT for retroperitoneal cancers: A case series and dosimetric analysis.

作者信息

Lee Shing Fung, Harris Nathanial, Yip Pui Lam, Dean Jenna, Geary Brayden, Koufogiannis George, Bauer Melanie, Joon Daryl Lim, Foroudi Farshad, Choong Ee Siang, Chao Michael

机构信息

Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore.

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

出版信息

Clin Transl Radiat Oncol. 2025 Mar 8;52:100943. doi: 10.1016/j.ctro.2025.100943. eCollection 2025 May.

Abstract

OBJECTIVES

To evaluate the clinical indications, post-operative complications, and dosimetric impact of stabilized hyaluronic acid (sHA) spacer insertion in the retroperitoneum for stereotactic body radiation therapy (SBRT) of retroperitoneal cancers.

PATIENTS AND METHODS

This retrospective study analyzed two cases of SBRT for retroperitoneal lesions: a primary left renal cell carcinoma and an oligometastatic renal cell carcinoma (RCC) lesion in the right adrenal gland. In both cases, a sHA spacer was percutaneously inserted between the bowel and the lesion. The spacer was placed under laparoscopic and ultrasound guidance for the renal tumor, and under CT guidance for the adrenal lesion. The prescribed dose was 42 Gy in three fractions for the primary renal lesion and 40 Gy in five fractions for the adrenal lesion. Dosimetric parameters were evaluated in two planning scenarios: (1) without the spacer, adhering to OAR constraints, and (2) with the spacer.

RESULTS

Spacer insertion for the primary left renal cancer significantly improved PTV D95% from 67.9 % to 99.5 % of the prescribed dose, a 46.5 % increase. PTV D99% increased from 54.5 % to 86.7 %, reflecting a 59.1 % improvement. The large bowel's maximum dose was reduced from 28.2 Gy to 24.4 Gy, and the volume receiving 24 Gy was minimal with the spacer (0.06 cc). For the right oligometastatic adrenal lesion, despite a fourfold increase in tumor volume, post-spacer dosimetry showed improved PTV coverage without exceeding OAR constraints. No post-operative complications were observed in either case.

CONCLUSION

This is the first report on sHA spacer use in the retroperitoneum for SBRT. Spacer insertion near the large bowel significantly improves dosimetry, enabling higher doses to targets while keeping OAR doses within safe limits. Further research with a larger patient population is required to assess safety and for optimization of the technique for spacer placement in order to enhance clinical outcomes.

摘要

目的

评估在腹膜后间隙插入稳定透明质酸(sHA)间隔物用于腹膜后癌立体定向体部放射治疗(SBRT)的临床适应症、术后并发症及剂量学影响。

患者与方法

本回顾性研究分析了2例腹膜后病变的SBRT病例:1例原发性左肾细胞癌和1例右肾上腺寡转移肾细胞癌(RCC)病变。两例均经皮在肠管与病变之间插入sHA间隔物。肾肿瘤的间隔物在腹腔镜和超声引导下放置,肾上腺病变的间隔物在CT引导下放置。原发性肾病变的处方剂量为42 Gy,分3次给予;肾上腺病变的处方剂量为40 Gy,分5次给予。在两种计划方案中评估剂量学参数:(1)不使用间隔物,遵循危及器官(OAR)限制;(2)使用间隔物。

结果

原发性左肾癌插入间隔物后,计划靶体积(PTV)的D95%从规定剂量的67.9%显著提高到99.5%,增加了46.5%。PTV的D99%从54.5%提高到86.7%,改善了59.1%。大肠的最大剂量从28.2 Gy降至24.4 Gy,使用间隔物时接受24 Gy照射的体积最小(0.06 cc)。对于右肾上腺寡转移病变,尽管肿瘤体积增加了4倍,但间隔物置入后的剂量学显示PTV覆盖改善,且未超过OAR限制。两例均未观察到术后并发症。

结论

这是关于在腹膜后间隙使用sHA间隔物进行SBRT的首例报告。在大肠附近插入间隔物可显著改善剂量学,使靶区能接受更高剂量照射,同时将OAR剂量控制在安全范围内。需要对更多患者进行进一步研究,以评估安全性并优化间隔物放置技术,从而提高临床疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c4d5/11950742/86764ab0dd37/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验